Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

Noriko Satoh, Yoshihiro Ogawa, Takeshi Usui, Tetsuya Tagami, Shigeo Kono, Hiroko Uesugi, Hiroyuki Sugiyama, Akira Sugawara, Kazunori Yamada, Akira Shimatsu, Hideshi Kuzuya, Kazuwa Nakao

Research output: Contribution to journalArticle

277 Citations (Scopus)

Abstract

OBJECTIVE - Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the relationship between the antiatherogenic and antidiabetic effects of pioglitazone, a TZD, in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A total of 136 Japanese type 2 diabetic patients were included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3 months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid metabolism as well as plasma high-sensitivity C-reactive protein (CRP), leptin, adiponectin, and pulse wave velocity (PWV) were monitored to analyze the relationship between the antiatherogenic and antidiabetic effects of pioglitazone. RESULTS - The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA1c levels and increased plasma adiponectin concentrations relative to the control group (P < 0.01). It also significantly decreased CRP and PWV (P < 0.01). The antiatherogenic effect was observed in both the nonresponders showing < 1% of reduction in HbA1c (n = 30) and responders showing > 1% of reduction (n = 40). ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. CONCLUSIONS - This study represents the first demonstration of the antiatherogenic effect of pioglitazone in both nonresponders and responders with respect to its antidiabetic effect and suggests that pioglitazone can exert its antiatherogenic effect independently of its antidiabetic effect.

Original languageEnglish
Pages (from-to)2493-2499
Number of pages7
JournalDiabetes care
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

pioglitazone
Hypoglycemic Agents
Thiazolidinediones
Pulse Wave Analysis
Adiponectin
C-Reactive Protein
Control Groups
Glycolipids
Hyperinsulinism
Leptin
Hyperglycemia
Type 2 Diabetes Mellitus
Research Design

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. / Satoh, Noriko; Ogawa, Yoshihiro; Usui, Takeshi; Tagami, Tetsuya; Kono, Shigeo; Uesugi, Hiroko; Sugiyama, Hiroyuki; Sugawara, Akira; Yamada, Kazunori; Shimatsu, Akira; Kuzuya, Hideshi; Nakao, Kazuwa.

In: Diabetes care, Vol. 26, No. 9, 01.09.2003, p. 2493-2499.

Research output: Contribution to journalArticle

Satoh, N, Ogawa, Y, Usui, T, Tagami, T, Kono, S, Uesugi, H, Sugiyama, H, Sugawara, A, Yamada, K, Shimatsu, A, Kuzuya, H & Nakao, K 2003, 'Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect', Diabetes care, vol. 26, no. 9, pp. 2493-2499. https://doi.org/10.2337/diacare.26.9.2493
Satoh, Noriko ; Ogawa, Yoshihiro ; Usui, Takeshi ; Tagami, Tetsuya ; Kono, Shigeo ; Uesugi, Hiroko ; Sugiyama, Hiroyuki ; Sugawara, Akira ; Yamada, Kazunori ; Shimatsu, Akira ; Kuzuya, Hideshi ; Nakao, Kazuwa. / Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. In: Diabetes care. 2003 ; Vol. 26, No. 9. pp. 2493-2499.
@article{f685ce2242d747a98887062877c92f2c,
title = "Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect",
abstract = "OBJECTIVE - Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the relationship between the antiatherogenic and antidiabetic effects of pioglitazone, a TZD, in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A total of 136 Japanese type 2 diabetic patients were included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3 months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid metabolism as well as plasma high-sensitivity C-reactive protein (CRP), leptin, adiponectin, and pulse wave velocity (PWV) were monitored to analyze the relationship between the antiatherogenic and antidiabetic effects of pioglitazone. RESULTS - The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA1c levels and increased plasma adiponectin concentrations relative to the control group (P < 0.01). It also significantly decreased CRP and PWV (P < 0.01). The antiatherogenic effect was observed in both the nonresponders showing < 1{\%} of reduction in HbA1c (n = 30) and responders showing > 1{\%} of reduction (n = 40). ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. CONCLUSIONS - This study represents the first demonstration of the antiatherogenic effect of pioglitazone in both nonresponders and responders with respect to its antidiabetic effect and suggests that pioglitazone can exert its antiatherogenic effect independently of its antidiabetic effect.",
author = "Noriko Satoh and Yoshihiro Ogawa and Takeshi Usui and Tetsuya Tagami and Shigeo Kono and Hiroko Uesugi and Hiroyuki Sugiyama and Akira Sugawara and Kazunori Yamada and Akira Shimatsu and Hideshi Kuzuya and Kazuwa Nakao",
year = "2003",
month = "9",
day = "1",
doi = "10.2337/diacare.26.9.2493",
language = "English",
volume = "26",
pages = "2493--2499",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

AU - Satoh, Noriko

AU - Ogawa, Yoshihiro

AU - Usui, Takeshi

AU - Tagami, Tetsuya

AU - Kono, Shigeo

AU - Uesugi, Hiroko

AU - Sugiyama, Hiroyuki

AU - Sugawara, Akira

AU - Yamada, Kazunori

AU - Shimatsu, Akira

AU - Kuzuya, Hideshi

AU - Nakao, Kazuwa

PY - 2003/9/1

Y1 - 2003/9/1

N2 - OBJECTIVE - Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the relationship between the antiatherogenic and antidiabetic effects of pioglitazone, a TZD, in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A total of 136 Japanese type 2 diabetic patients were included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3 months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid metabolism as well as plasma high-sensitivity C-reactive protein (CRP), leptin, adiponectin, and pulse wave velocity (PWV) were monitored to analyze the relationship between the antiatherogenic and antidiabetic effects of pioglitazone. RESULTS - The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA1c levels and increased plasma adiponectin concentrations relative to the control group (P < 0.01). It also significantly decreased CRP and PWV (P < 0.01). The antiatherogenic effect was observed in both the nonresponders showing < 1% of reduction in HbA1c (n = 30) and responders showing > 1% of reduction (n = 40). ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. CONCLUSIONS - This study represents the first demonstration of the antiatherogenic effect of pioglitazone in both nonresponders and responders with respect to its antidiabetic effect and suggests that pioglitazone can exert its antiatherogenic effect independently of its antidiabetic effect.

AB - OBJECTIVE - Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the relationship between the antiatherogenic and antidiabetic effects of pioglitazone, a TZD, in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A total of 136 Japanese type 2 diabetic patients were included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3 months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid metabolism as well as plasma high-sensitivity C-reactive protein (CRP), leptin, adiponectin, and pulse wave velocity (PWV) were monitored to analyze the relationship between the antiatherogenic and antidiabetic effects of pioglitazone. RESULTS - The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA1c levels and increased plasma adiponectin concentrations relative to the control group (P < 0.01). It also significantly decreased CRP and PWV (P < 0.01). The antiatherogenic effect was observed in both the nonresponders showing < 1% of reduction in HbA1c (n = 30) and responders showing > 1% of reduction (n = 40). ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. CONCLUSIONS - This study represents the first demonstration of the antiatherogenic effect of pioglitazone in both nonresponders and responders with respect to its antidiabetic effect and suggests that pioglitazone can exert its antiatherogenic effect independently of its antidiabetic effect.

UR - http://www.scopus.com/inward/record.url?scp=10744225126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744225126&partnerID=8YFLogxK

U2 - 10.2337/diacare.26.9.2493

DO - 10.2337/diacare.26.9.2493

M3 - Article

VL - 26

SP - 2493

EP - 2499

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -